Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pulmonology
•
Obstructive Lung Disease
•
Primary Care
What is your approach to de-escalation of asthma therapy if patients have remained clinically stable on triple inhaler therapy and a biologic agent?
Answer from: at Community Practice
Since the reason most folks need biologics is prednisone and considering the side effects, getting patients down to the lowest dose is beneficial.
Sign in or Register to read more
23325
Related Questions
What is your approach to de-escalation of asthma inhaler therapy in the setting of negative bronchoprovocation testing when patients are averse to deprescribing?
Do you routinely consider evaluation for EDAC in patients with asthma or COPD on maximal inhaler therapy who have refractory symptoms?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
Do you plan to use benralizumab to treat acute exacerbations of asthma or COPD associated with eosinophilia?
How do you manage daytime somnolence without a clear cause?
What is your approach to helping parents manage sleep disturbances in patients with autism spectrum disorder?
What is your preferred biologic in children and adolescents with T2 high asthma?
Do you implement FEV3/FEV6 or FEF25-75 measurements in the evaluation of patients for small airways obstruction?